A product launches. Uptake is slow. Within a few months someone in the room says the obvious thing: the price is too high. Sometimes that is true. Often it is not, and the company spends its most valuable concession fixing a problem it does not have.
Before anyone touches price, it is worth asking where exactly patients are being lost.
Map the path before you blame the gate
Every patient who should receive a medicine passes through a series of steps. Each step is a place where they can drop out.
- Diagnosis. Is the patient identified at all? Under-diagnosis is common in many conditions, and no price change will find an undiagnosed patient.
- Referral. Does the patient reach a physician who can prescribe? In many systems the eligible prescriber sits in a small number of specialist centers.
- Listing. Is the medicine on the formulary of the institution or payer that covers this patient? Listing in one sector says nothing about another.
- Prescribing. Do physicians know the evidence, trust it, and know the patient qualifies under the listing criteria?
- Dispensing and continuation. Is the medicine actually available in the pharmacy, and do patients stay on it?
A pricing problem shows up at one of these steps, usually listing. If the leak is somewhere else, price is not your lever.
Signs it is not about price
- The medicine is listed, but prescriptions are concentrated in a handful of centers.
- Payers have not formally rejected the price. The file is simply waiting.
- The committee asked questions about the evidence, the population or the comparator, not the cost.
- Uptake is fine in one sector and weak in another with similar budgets.
Ask the payer's question, not yours
When a decision stalls, the useful question is what the decision maker would need to see in order to say yes. The answer might be a clearer definition of the eligible population, local data, a budget forecast they believe, or a way to limit uncertainty. Each of those has a solution that costs far less than a permanent price reduction.
Price is one answer. Make sure you have asked the right question first.
Strong Access professionals hold the price conversation back until they can show which step is failing and why. That discipline protects the product, and it builds credibility with the payer, who can tell the difference between a company that understands their system and one that only wants a decision.